ASCO 2019: First-line immunotherapy combinations in metastatic kidney cancer
This presentation from the American Society of Clinical Oncology (ASCO) [...]
ASCO 2019: Active surveillance in metastatic kidney cancer
This study used data from the Canadian Kidney Cancer Information [...]
ASCO 2019: Analysis of CARMENA trial results using IMDC risk groups
The results from CARMENA, a randomised phase III clinical trial [...]
ASCO 2019: Biomarkers for advanced renal cell carcinoma from the JAVELIN Renal 101 study
Results from the biomarker analysis from the JAVALIN Renal 101 [...]
Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer
Results from this phase III trial of atezolizumab plus bevacizumab [...]
First CAR-T therapy for kidney cancer shows signs of efficacy
Chimeric antigen receptor T-cell (CAR-T) therapy is an immunotherapy specifically [...]
Predictive biomarkers in metastatic kidney cancer
A review published in European Urology Focus looks at tools [...]
Intermittent nivolumab in the second line warrants further investigation
A recent phase 2 trial published in Journal for Immunotherapy [...]
Neoadjuvant axitinib to allow partial nephrectomy of cT2a renal tumours
A phase 2 study published in the British Journal of [...]
Real-world outcomes of nivolumab and cabozantinib for metastatic kidney cancer
A retrospective study using data from the International Metastatic Renal [...]
